1. Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels
- Author
-
Torben Hansen, Julie R. Lundgren, Yuvaraj Mahendran, Eva W. Iepsen, Sten Madsbad, Line Engelbrechtsen, Signe S. Torekov, Anna Jonsson, Jens J. Holst, Henrik Vestergaard, and Ehm A. Andersson
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Branched-chain amino acid ,030209 endocrinology & metabolism ,Phenylalanine ,Type 2 diabetes ,medicine.disease ,Biochemistry ,03 medical and health sciences ,chemistry.chemical_compound ,030104 developmental biology ,0302 clinical medicine ,Insulin resistance ,Endocrinology ,chemistry ,Valine ,Weight loss ,Internal medicine ,medicine ,Isoleucine ,Leucine ,medicine.symptom - Abstract
Increased levels of circulating branched chain amino acids (BCAAs), as well as phenylalanine, and tyrosine have been suggested to be involved in the pathogenesis of insulin resistance and type 2 diabetes. However, it is unknown how these metabolites are affected by weight loss, and during weight-maintaining treatment with glucagon-like peptide-1 receptor agonist (GLP-1 RA). We aimed to characterize changes in metabolites related to protein turnover and glycolysis after a weight loss intervention followed by long term weight maintenance with/without GLP-1 RA. Fifty-eight obese individuals underwent a diet-induced 12 % body weight loss during 8 weeks. Participants were randomized to weight maintenance with or without administration of the GLP-1 RA liraglutide (1.2 mg/day) for 52 weeks. Metabolomic profiling by high-throughput proton nuclear magnetic resonance spectroscopy was used for quantification of metabolites. The weight loss was maintained in both groups and was associated with 9–20 % decreases in plasma concentrations of alanine, phenylalanine, histidine, tyrosine and the BCAAs leucine, isoleucine and valine (p
- Published
- 2016